Clinical Focus


  • Pediatric Critical Care Medicine

Academic Appointments


Administrative Appointments


  • James Baxter Wood and Yvonne Craig Wood Endowed Director of the Pediatric CVICU, LPCH (2026 - Present)

Professional Education


  • Board Certification: American Board of Pediatrics, Pediatric Critical Care Medicine (2023)
  • Fellowship: Stanford University Cardiovascular Medicine Fellowship CA
  • Medical Education: Boston University School of Medicine (2008) MA
  • Fellowship: UCSF Pediatric Critical Care Medicine Fellowship (2015) CA
  • Residency: Boston Children's Hospital (2011) MA

All Publications


  • Beyond Census: Building a Novel Unit-Level Acuity Score for Capacity Assessment and Outcomes Prediction in a Pediatric Cardiovascular Intensive Care Unit Kameny, R., Meng, J., Kim, K., Thomas, H., Dhillon, A., Le, J., Rigby, B., Scheinker, D., Shin, A., Patel, M. D. LIPPINCOTT WILLIAMS & WILKINS. 2026: A18720
  • Recent advances in the clinical management of end-stage pediatric pulmonary hypertension. Current opinion in pulmonary medicine van der Have, O., Hopper, R. K., Kameny, R. J., Tran-Lundmark, K. 2026

    Abstract

    This review aims to give an overview of recent advances in the clinical management of children <18 years of age with end-stage pulmonary hypertension refractory to conventional medical therapy.The increased awareness and characterization of pediatric pulmonary vascular disease has amounted more data toward creating an accurate, and comprehensive, risk prediction tool. This underscores the importance of serial outpatient re-assessment, as early consideration of advanced pharmaceutical and interventional therapies, as well as lung transplantation, improves outcomes in children. Despite the emergence and approval of new therapies against pulmonary hypertension in adults, pediatric-specific complications have not yet been adequately explored. It is, however, encouraging that several trials are ongoing to address this issue. Interventional strategies to unload the right ventricle are increasingly being utilized, although evidence remains scarce in this area. Extra-corporeal membrane oxygenation may, in addition to being a bridge to lung transplantation in well-selected patients, be considered as a bridge to catheter-based or surgical interventions. Management of pediatric right ventricular failure in the setting of advanced pulmonary hypertension is a truly complex clinical challenge at the intersection of cardiac, vascular and respiratory physiology and requires careful integration of invasive hemodynamic assessment, pulmonary vasodilator therapy, ventilatory strategy, and timely consideration of mechanical circulatory support.

    View details for DOI 10.1097/MCP.0000000000001283

    View details for PubMedID 42158971

  • Cardiology Overview of Pulmonary Hypertension Management in the Neonatal Intensive Care Unit. Clinics in perinatology Kameny, R. J., Hopper, R. K. 2025; 52 (4): 633-653

    Abstract

    Pulmonary hypertension (PH) in the neonatal intensive care unit represents a complex and diverse spectrum of conditions, from transient persistent pulmonary hypertension of the newborn to chronic PH associated with bronchopulmonary dysplasia, congenital heart disease, and other conditions, and can cause significant morbidity and mortality. Proper classification, timely diagnosis using echocardiography and imaging, and tailored therapy are essential. A multidisciplinary approach is critical, particularly for infants with unclear or genetic causes. This article provides a thorough overview of the current classification schema of pulmonary hypertension, underlying pathophysiology, diagnostic work-up, treatment options, and long-term prognosis.

    View details for DOI 10.1016/j.clp.2025.08.002

    View details for PubMedID 41233002

  • A Joint Perspective on End-of-Life Care in Pediatric Pulmonary Hypertension. Pulmonary circulation Kameny, R., Van Wormer, S., Varghese, N. P. 2025; 15 (4): e70181

    View details for DOI 10.1002/pul2.70181

    View details for PubMedID 41141406

    View details for PubMedCentralID PMC12548778

  • Randomized, Placebo-Controlled Trial of Peri-Operative Treprostinil in Pediatric Patients Undergoing the Fontan Operation. Pulmonary circulation Sullivan, R. T., Handler, S. S., Arunamata, A. A., Ogawa, M. T., Liu, E., Lu, D., Martin, E., Ramamoorthy, C., Kameny, R., Feinstein, J. A. 2025; 15 (3): e70122

    Abstract

    The objective of this study is to assess the effect of subcutaneous treprostinil (TRE) administered peri-operatively after Fontan operation on chest tube duration (CTD), hospital length of stay (LOS), and post-operative hemodynamics. This is a single center randomized, blinded, placebo-controlled study of pediatric patients with single ventricle congenital heart disease undergoing Fontan operation between September 2015 and September 2019. Patients were randomized to receive subcutaneous TRE (target dose 10 ng/kg/min) or saline placebo starting intraoperatively through post-operative day 7. Baseline demographics, pre-operative hemodynamics, and peri-operative clinical details were collected. The primary outcome was CTD. Secondary outcomes included hospital LOS and hemodynamics. Thirty-four patients were randomized, 16 to TRE and 18 to saline placebo. Baseline characteristics were similar between groups, including pre-operative hemodynamics. Patients receiving TRE had increased risk for longer CTD (median CTD 8 vs. 7 days compared to placebo [IQR: 7-12.5, 5-8 days, respectively] with a relative risk (RR) of 1.29 (95% CI: 1.02, 1.64; p = 0.03)) and increased risk for longer hospital LOS (median LOS 11 vs. 9 days compared to placebo [IQR: 9.5-14.5, 8-10 days, respectively] with a RR of 1.23 (95% CI: 1.00, 1.51; p = 0.05)). Patients receiving TRE had higher median Fontan pressure at post-operative hour 12 (13 mmHg [IQR: 12.5-15.0] vs. 10.5 mmHg [IQR: 8.0-12.5]; p < 0.01 on repeated measure analysis model) and greater transpulmonary gradient at post-operative hour 12 (7.0 mmHg [IQR: 5.0-9.5] vs. 4.0 mmHg [IQR: 3.5-5.0]; p < 0.01 on repeated measure analysis model) compared to placebo. Peri-operative subcutaneous TRE did not reduce CTD or hospital LOS after Fontan operation and did not exert significant beneficial effects on post-operative hemodynamics. Accordingly, TRE at a dose of 10 ng/kg/min is not recommended for routine use in immediate post-operative Fontan management.

    View details for DOI 10.1002/pul2.70122

    View details for PubMedID 40672982

    View details for PubMedCentralID PMC12263512

  • THE COMFORT ZONE: IMPLEMENTATION OF AN ANALGESIA AND SEDATION PROTOCOL IN A PEDIATRIC CVICU Xie, A., Khlifi, K., Chau, A., Kameny, R., Presnell, L., Sandler, B. LIPPINCOTT WILLIAMS & WILKINS. 2025
  • Racial and Ethnic Disparities in Cardiac Reintervention after Pediatric Cardiac Surgery. The Annals of thoracic surgery Saha, P., Tjoeng, Y. L., Algaze, C., Kameny, R., Pinto, N., Chan, T. 2023

    Abstract

    BACKGROUND: Children undergoing cardiac surgery may require postoperative surgical or catheter-based reintervention prior to discharge. We examined racial/ethnic variations in reintervention and associated in-hospital mortality.METHODS: Children undergoing cardiac surgery from 2004 to 2015 were identified in the Pediatric Health Information Systems (PHIS) database. Regression analysis measured associations between race/ethnicity, in-hospital mortality, and postoperative cardiac surgical or catheter-based reintervention (Surgery/Catheter Reintervention).RESULTS: Of 124,263 patients, 8,265 (6.7%) had a Surgery/Catheter Reintervention. Black patients had fewer reinterventions (5.9% versus 6.7%) and higher in-hospital mortality (3.9% versus 2.7%, p<0.01) than White patients. After adjusting for sociodemographic and illness severity indicators, Black patients remained less likely to receive Surgery/Catheter Reintervention (adjusted Hazard Ratio [aHR] 0.89, 95% confidence interval [CI] 0.82-0.98) despite having similar risk of death after reintervention (adjusted Odds Ratio [aOR] 1.17, 95% CI 0.98-1.41) compared with White patients. Black and Other race/ethnicity patients also had higher risk of death without Surgery/Catheter Reintervention (aHR 1.26, 95% CI 1.08-1.47 and aHR 1.33, 95% CI 1.13-1.57, respectively) than White patients. Similar trends were demonstrated when mechanical circulatory support and cardiac transplantation were included as reinterventions.CONCLUSIONS: Patients of Black and Other race/ethnicity undergoing pediatric cardiac surgery are more likely to die without postoperative cardiac reintervention than White patients. Black patients are also less likely to receive reintervention despite no significant difference in mortality with reintervention. Further studies should evaluate etiologies and methods of addressing these disparities.

    View details for DOI 10.1016/j.athoracsur.2023.10.027

    View details for PubMedID 37923240

  • Pulmonary Vasodilator Therapy in Pediatric Patients on Ventricular Assist Device Support: A Single-Center Experience and Proposal for Use. ASAIO journal (American Society for Artificial Internal Organs : 1992) Schramm, J. E., Dykes, J. C., Hopper, R. K., Feinstein, J. A., Rosenthal, D. N., Kameny, R. J. 2023

    Abstract

    Pediatric precapillary pulmonary hypertension can develop in response to systemic atrial hypertension. Systemic atrial decompression following ventricular assist device (VAD) implantation may not sufficiently lower pulmonary vascular resistance (PVR) to consider heart transplant candidacy. Prostacyclins have been used in adult VAD patients with success, but pediatric data on safety and efficacy in this population are limited. We sought to describe our center's experience to show its safety and to present our current protocol for perioperative use. We reviewed our use of prostacyclin therapy in pediatric patients on VAD support with high PVR from 2016 to 2021. Of the 17 patients who met inclusion, 12 survived to transplant and 1 is alive with VAD in situ. All patients survived posttransplant. With continuous intravenous (IV) epoprostenol or treprostinil therapy, there were no bleeding complications or worsening of end-organ function. A significant reduction was observed in vasoactive inotropic scores by 49% in the first 24 hours post-prostacyclin initiation. The proportion of patients surviving to transplant in this high-risk cohort is favorable. In conclusion, prostacyclins may be safe to use in patients with elevated PVR as part of their VAD and transplant course and may provide a transplant option in those otherwise not candidates.

    View details for DOI 10.1097/MAT.0000000000002023

    View details for PubMedID 37556563

  • Measures for Improving Health Equity in Pediatric Cardiology Harmeling, A., Leonard, M., Kipps, A., Shin, A., Palmon, M., Kameny, R. LIPPINCOTT WILLIAMS & WILKINS. 2022: A15843
  • A case of acquired von Willebrand disease in severe pediatric pulmonary hypertension contributing to bleeding following reverse Potts shunt. Pulmonary Circulation Sullivan, R. T., Lo, C., Martin, E., Kameny, R. J., Hopper, R. K. 2022; 12 (e12042)

    View details for DOI 10.1002/pul2.12042

  • A case of acquired von Willebrand disease in severe pediatric pulmonary hypertension contributing to bleeding following reverse Potts shunt. Pulmonary circulation Sullivan, R. T., Lo, C., Martin, E., Kameny, R. J., Hopper, R. K. 2022; 12 (1): e12042

    Abstract

    The reverse Potts shunt is increasingly used as a palliative measure for end-stage pulmonary arterial hypertension (PAH) as a means to offload the right ventricle and improve functional status. This case report describes a child who developed significant hemothorax after reverse Potts shunt that required surgical exploration, blood product administration, and prolonged intensive care hospitalization. Despite lack of preoperative bleeding symptoms, testing revealed acquired von Willebrand disease (aVWD), with subsequent resolution of bleeding. Alterations in von Willebrand factor, including aVWD, have been reported in children with severe PAH but have not previously been associated with bleeding after reverse Potts shunt procedure. As bleeding is a recognized postoperative morbidity in PAH patients undergoing reverse Potts shunt, we highlight a potential role for preoperative testing for aVWD as perioperative factor replacement therapy may improve postoperative outcomes.

    View details for DOI 10.1002/pul2.12042

    View details for PubMedID 35506098

    View details for PubMedCentralID PMC9052962

  • HIF-1α promotes cellular growth in lymphatic endothelial cells exposed to chronically elevated pulmonary lymph flow SCIENTIFIC REPORTS Boehme, J. T., Morris, C. J., Chiacchia, S. R., Gong, W., Wu, K. Y., Kameny, R. J., Raff, G. W., Fineman, J. R., Maltepe, E., Datar, S. A. 2021; 11 (1): 1468

    Abstract

    Normal growth and development of lymphatic structures depends on mechanical forces created by accumulating interstitial fluid. However, prolonged exposure to pathologic mechanical stimuli generated by chronically elevated lymph flow results in lymphatic dysfunction. The mechanisms that transduce these mechanical forces are not fully understood. Our objective was to investigate molecular mechanisms that alter the growth and metabolism of isolated lymphatic endothelial cells (LECs) exposed to prolonged pathologically elevated lymph flow in vivo within the anatomic and physiologic context of a large animal model of congenital heart disease with increased pulmonary blood flow using in vitro approaches. To this end, late gestation fetal lambs underwent in utero placement of an aortopulmonary graft (shunt). Four weeks after birth, LECs were isolated and cultured from control and shunt lambs. Redox status and proliferation were quantified, and transcriptional profiling and metabolomic analyses were performed. Shunt LECs exhibited hyperproliferative growth driven by increased levels of Hypoxia Inducible Factor 1α (HIF-1α), along with upregulated expression of known HIF-1α target genes in response to mechanical stimuli and shear stress. Compared to control LECs, shunt LECs exhibited abnormal metabolism including abnormalities of glycolysis, the TCA cycle and aerobic respiration. In conclusion, LECs from lambs exposed in vivo to chronically increased pulmonary lymph flow are hyperproliferative, have enhanced expression of HIF-1α and its target genes, and demonstrate altered central carbon metabolism in vitro. Importantly, these findings suggest provocative therapeutic targets for patients with lymphatic abnormalities.

    View details for DOI 10.1038/s41598-020-80882-1

    View details for Web of Science ID 000626775600068

    View details for PubMedID 33446832

    View details for PubMedCentralID PMC7809484

  • Mechanical forces alter endothelin-1 signaling: comparative ovine models of congenital heart disease PULMONARY CIRCULATION Zhu, T., Chiacchia, S., Kameny, R. J., De Herreros, A., Gong, W., Raff, G. W., Boehme, J. B., Maltepe, E., Lasheras, J. C., Black, S. M., Datar, S. A., Fineman, J. R. 2020; 10 (2): 2045894020922118

    Abstract

    The risk and progression of pulmonary vascular disease in patients with congenital heart disease is dependent on the hemodynamics associated with different lesions. However, the underlying mechanisms are not understood. Endothelin-1 is a potent vasoconstrictor that plays a key role in the pathology of pulmonary vascular disease. We utilized two ovine models of congenital heart disease: (1) fetal aortopulmonary graft placement (shunt), resulting in increased flow and pressure; and (2) fetal ligation of the left pulmonary artery resulting in increased flow and normal pressure to the right lung, to investigate the hypothesis that high pressure and flow, but not flow alone, upregulates endothelin-1 signaling. Lung tissue and pulmonary arterial endothelial cells were harvested from control, shunt, and the right lung of left pulmonary artery lambs at 3-7 weeks of age. We found that lung preproendothelin-1 mRNA and protein expression were increased in shunt lambs compared to controls. Preproendothelin-1 mRNA expression was modestly increased, and protein was unchanged in left pulmonary artery lambs. These changes resulted in increased lung endothelin-1 levels in shunt lambs, while left pulmonary artery levels were similar to controls. Pulmonary arterial endothelial cells exposed to increased shear stress decreased endothelin-1 levels by five-fold, while cyclic stretch increased levels by 1.5-fold. These data suggest that pressure or an additive effect of pressure and flow, rather than increased flow alone, is the principal driver of increased endothelin signaling in congenital heart disease. Defining the molecular drivers of the pathobiology of pulmonary vascular disease due to differing mechanical forces will allow for a more targeted therapeutic approach.

    View details for DOI 10.1177/2045894020922118

    View details for Web of Science ID 000535935000001

    View details for PubMedID 32489641

    View details for PubMedCentralID PMC7238833

  • miR-486 is modulated by stretch and increases ventricular growth JCI INSIGHT Lange, S., Banerjee, I., Carrion, K., Serrano, R., Habich, L., Kameny, R., Lengenfelder, L., Dalton, N., Meili, R., Boergeson, E., Peterson, K., Ricci, M., Lincoln, J., Ghassemian, M., Fineman, J., del Alamo, J. C., Nigam, V. 2019; 4 (19)

    Abstract

    Perturbations in biomechanical stimuli during cardiac development contribute to congenital cardiac defects such as hypoplastic left heart syndrome (HLHS). This study sought to identify stretch-responsive pathways involved in cardiac development. miRNA-Seq identified miR-486 as being increased in cardiomyocytes exposed to cyclic stretch in vitro. The right ventricles (RVs) of patients with HLHS experienced increased stretch and had a trend toward higher miR-486 levels. Sheep RVs dilated from excessive pulmonary blood flow had 60% more miR-486 compared with control RVs. The left ventricles of newborn mice treated with miR-486 mimic were 16.9%-24.6% larger and displayed a 2.48-fold increase in cardiomyocyte proliferation. miR-486 treatment decreased FoxO1 and Smad signaling while increasing the protein levels of Stat1. Stat1 associated with Gata-4 and serum response factor (Srf), 2 key cardiac transcription factors with protein levels that increase in response to miR-486. This is the first report to our knowledge of a stretch-responsive miRNA that increases the growth of the ventricle in vivo.

    View details for DOI 10.1172/jci.insight.125507

    View details for Web of Science ID 000488988500002

    View details for PubMedID 31513548

    View details for PubMedCentralID PMC6795397

  • Ovine Models of Congenital Heart Disease and the Consequences of Hemodynamic Alterations for Pulmonary Artery Remodeling AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY Kameny, R., Datar, S. A., Boehme, J. B., Morris, C., Zhu, T., Goudy, B. D., Johnson, E. G., Galambos, C., Raff, G. W., Sun, X., Wang, T., Chiacchia, S. R., Lu, Q., Black, S. M., Maltepe, E., Fineman, J. R. 2019; 60 (5): 503-514

    Abstract

    The natural history of pulmonary vascular disease associated with congenital heart disease (CHD) depends on associated hemodynamics. Patients exposed to increased pulmonary blood flow (PBF) and pulmonary arterial pressure (PAP) develop pulmonary vascular disease more commonly than patients exposed to increased PBF alone. To investigate the effects of these differing mechanical forces on physiologic and molecular responses, we developed two models of CHD using fetal surgical techniques: 1) left pulmonary artery (LPA) ligation primarily resulting in increased PBF and 2) aortopulmonary shunt placement resulting in increased PBF and PAP. Hemodynamic, histologic, and molecular studies were performed on control, LPA, and shunt lambs as well as pulmonary artery endothelial cells (PAECs) derived from each. Physiologically, LPA, and to a greater extent shunt, lambs demonstrated an exaggerated increase in PAP in response to vasoconstricting stimuli compared with controls. These physiologic findings correlated with a pathologic increase in medial thickening in pulmonary arteries in shunt lambs but not in control or LPA lambs. Furthermore, in the setting of acutely increased afterload, the right ventricle of control and LPA but not shunt lambs demonstrates ventricular-vascular uncoupling and adverse ventricular-ventricular interactions. RNA sequencing revealed excellent separation between groups via both principal components analysis and unsupervised hierarchical clustering. In addition, we found hyperproliferation of PAECs from LPA lambs, and to a greater extent shunt lambs, with associated increased angiogenesis and decreased apoptosis in PAECs derived from shunt lambs. A further understanding of mechanical force-specific drivers of pulmonary artery pathology will enable development of precision therapeutics for pulmonary hypertension associated with CHD.

    View details for DOI 10.1165/rcmb.2018-0305MA

    View details for Web of Science ID 000466716000007

    View details for PubMedID 30620615

    View details for PubMedCentralID PMC6503613

  • Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic (vol 16, e2005924, 2018) PLOS BIOLOGY Boehme, J., Le Moan, N., Kameny, R. J., Loucks, A., Johengen, M. J., Lesneski, A. L., Gong, W., Goudy, B. D., Davis, T., Tanaka, K., Davis, A., He, Y., Long-Boyle, J., Ivaturi, V., Gobburu, J. V. S., Winger, J. A., Cary, S. P., Datar, S. A., Fineman, J. R., Krtolica, A., Maltepe, E. 2019; 17 (1): e3000119

    Abstract

    [This corrects the article DOI: 10.1371/journal.pbio.2005924.].

    View details for DOI 10.1371/journal.pbio.3000119

    View details for Web of Science ID 000559801200001

    View details for PubMedID 30677022

    View details for PubMedCentralID PMC6345423

  • Analysis of the microRNA signature driving adaptive right ventricular hypertrophy in an ovine model of congenital heart disease AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY Kameny, R., He, Y., Zhu, T., Gong, W., Raff, G. W., Chapin, C. J., Datar, S. A., Boehme, J. T., Hata, A., Fineman, J. R. 2018; 315 (4): H847-H854

    Abstract

    The right ventricular (RV) response to pulmonary arterial hypertension (PAH) is heterogeneous. Most patients have maladaptive changes with RV dilation and RV failure, whereas some, especially patients with PAH secondary to congenital heart disease, have an adaptive response with hypertrophy and preserved systolic function. Mechanisms for RV adaptation to PAH are unknown, despite RV function being a primary determinant of mortality. In our congenital heart disease ovine model with fetally implanted aortopulmonary shunt (shunt lambs), we previously demonstrated an adaptive physiological RV response to increased afterload with hypertrophy. In the present study, we examined small noncoding microRNA (miRNA) expression in shunt RV and characterized downstream effects of a key miRNA. RV tissue was harvested from 4-wk-old shunt and control lambs ( n = 5), and miRNA, mRNA, and protein were quantitated. We found differential expression of 40 cardiovascular-specific miRNAs in shunt RV. Interestingly, this miRNA signature is distinct from models of RV failure, suggesting that miRNAs might contribute to adaptive RV hypertrophy. Among RV miRNAs, miR-199b was decreased in the RV with eventual downregulation of nuclear factor of activated T cells/calcineurin signaling. Furthermore, antifibrotic miR-29a was increased in the shunt RV with a reduction of the miR-29 targets collagen type A1 and type 3A1 and decreased fibrosis. Thus, we conclude that the miRNA signature specific to shunt lambs is distinct from RV failure and drives gene expression required for adaptive RV hypertrophy. We propose that the adaptive RV miRNA signature may serve as a prognostic and therapeutic tool in patients with PAH to attenuate or prevent progression of RV failure and premature death. NEW & NOTEWORTHY This study describes a novel microRNA signature of adaptive right ventricular hypertrophy, with particular attention to miR-199b and miR-29a.

    View details for DOI 10.1152/ajpheart.00057.2018

    View details for Web of Science ID 000444689400011

    View details for PubMedID 29906222

    View details for PubMedCentralID PMC6230913

  • KLF2-mediated disruption of PPAR-γ signaling in lymphatic endothelial cells exposed to chronically increased pulmonary lymph flow AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY Morris, C. J., Kameny, R. J., Boehme, J., Gong, W., He, Y., Zhu, T., Maltepe, E., Raff, G. W., Fineman, J. R., Datar, S. A. 2018; 315 (1): H173-H181

    Abstract

    Lymphatic abnormalities associated with congenital heart disease are well described, yet the underlying mechanisms remain poorly understood. Using a clinically relevant ovine model of congenital heart disease with increased pulmonary blood flow, we have previously demonstrated that lymphatic endothelial cells (LECs) exposed in vivo to chronically increased pulmonary lymph flow accumulate ROS and have decreased bioavailable nitric oxide (NO). Peroxisome proliferator-activated receptor-γ (PPAR-γ), which abrogates production of cellular ROS by NADPH oxidase, is inhibited by Krüppel-like factor 2 (KLF2), a flow-induced transcription factor. We hypothesized that chronically increased pulmonary lymph flow induces a KLF2-mediated decrease in PPAR-γ and an accumulation of cellular ROS, contributing to decreased bioavailable NO in LECs. To better understand the mechanisms that transduce the abnormal mechanical forces associated with chronically increased pulmonary lymph flow, LECs were isolated from the efferent vessel of the caudal mediastinal lymph node of control ( n = 5) and shunt ( n = 5) lambs. KLF2 mRNA and protein were significantly increased in shunt compared with control LECs, and PPAR-γ mRNA and protein were significantly decreased. In control LECs exposed to shear forces in vitro, we found similar alterations to KLF2 and PPAR-γ expression. In shunt LECs, NADPH oxidase subunit expression was increased, and bioavailable NO was significantly lower. Transfection of shunt LECs with KLF2 siRNA normalized PPAR-γ, ROS, and bioavailable NO. Conversely, pharmacological inhibition of PPAR-γ in control LECs increased ROS equivalent to levels in shunt LECs at baseline. Taken together, these data suggest that one mechanism by which NO-mediated lymphatic function is disrupted after chronic exposure to increased pulmonary lymph flow is through altered KLF2-dependent PPAR-γ signaling, resulting in increased NADPH oxidase activity, accumulation of ROS, and decreased bioavailable NO. NEW & NOTEWORTHY Lymphatic endothelial cells, when exposed in vivo to chronically elevated pulmonary lymph flow in a model of congenital heart disease with increased pulmonary blood flow, demonstrate Krüppel-like factor 2-dependent disrupted peroxisome proliferator-activated receptor-γ signaling that results in the accumulation of reactive oxygen species and decreased bioavailable nitric oxide.

    View details for DOI 10.1152/ajpheart.00635.2017

    View details for Web of Science ID 000441144900018

    View details for PubMedID 29631374

    View details for PubMedCentralID PMC6087778

  • Initial presentation and management of pediatric heart failure. Current opinion in pediatrics Romer, A. J., Rajagopal, S. K., Kameny, R. J. 2018; 30 (3): 319-325

    Abstract

    Heart failure is a rare but morbid diagnosis in the pediatric patient presenting to the emergency department (ED). Familiarity of the ED physician with the presentation, work-up, and management of pediatric heart failure is essential as accurate diagnosis is reliant on a high degree of suspicion.Studies evaluating pediatric heart failure are limited by its rarity and the heterogeneity of underlying conditions. However, recent reports have provided new data on the epidemiology, presentation, and outcomes of children with heart failure.The recent studies reviewed here highlight the significant diagnostic and management challenges that pediatric heart failure presents given the variety and lack of specificity of its presenting signs, symptoms, and diagnostic work-up. This review provides the ED physician with a framework for understanding of pediatric heart failure to allow for efficient diagnosis and management of these patients. The primary focus of this review is heart failure in structurally normal hearts.

    View details for DOI 10.1097/MOP.0000000000000624

    View details for PubMedID 29528892

  • Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale LEUKEMIA & LYMPHOMA Zinter, M. S., Melton, A., Sabnis, A. J., Dvorak, C. C., Elicker, B. M., Nawaytou, H. M., Kameny, R. J., Fineman, J. R. 2018; 59 (6): 1494-1497

    View details for DOI 10.1080/10428194.2017.1382697

    View details for Web of Science ID 000437039400031

    View details for PubMedID 28958195

    View details for PubMedCentralID PMC5897181

  • Altered Carnitine Homeostasis in Children With Increased Pulmonary Blood Flow Due to Ventricular Septal Defects PEDIATRIC CRITICAL CARE MEDICINE Black, S. M., Field-Ridley, A., Sharma, S., Kumar, S., Keller, R. L., Kameny, R., Maltepe, E., Datar, S. A., Fineman, J. R. 2017; 18 (10): 931-934

    Abstract

    Congenital heart disease with increased pulmonary blood flow results in progressive pulmonary vascular endothelial dysfunction and associated increased perioperative morbidity. Using our ovine model of congenital heart disease with increased pulmonary blood flow, we have previously demonstrated progressive endothelial dysfunction associated with disruption in carnitine homeostasis, mitochondrial dysfunction, decreased nitric oxide signaling, and enhanced reactive oxygen species generation. However, potential alterations in these parameters in patients with congenital heart disease have not been investigated. The objective of this study was to test the hypothesis that children with increased pulmonary blood flow will have evidence of altered carnitine homeostasis, mitochondrial dysfunction, decreased nitric oxide levels, and increased reactive oxygen species generation.A prospective single-center cohort study.A tertiary care cardiac ICU/PICU.Arterial blood samples from 18 patients with congenital heart disease associated with increased pulmonary blood flow (ventricular septal defect), 20 with congenital heart disease without increased pulmonary blood flow (tetralogy of Fallot), and 10 without heart disease (controls) were obtained.Plasma levels of total carnitine, free carnitine, acylcarnitine, and lactate-to-pyruvate ratios, an indicator of mitochondrial function, were determined and compared. In addition, levels of superoxide and hydrogen peroxide were determined and compared in patients with ventricular septal defect and controls. Statistical analysis was performed using an unpaired t test and analysis of variance.Baseline acylcarnitine levels (25.7 ± 13 vs 12.7 ± 8.3; p < 0.05), the acylcarnitine-to-free carnitine ratio (0.8 ± 0.1 vs 0.3 ± 0.05; p < 0.05), and the lactate-to-pyruvate ratio were higher in ventricular septal defect (27.5 ± 3.8 vs 11.1 ± 4.1, p < 0.05) than tetralogy of Fallot; there were no differences between tetralogy of Fallot and control. Superoxide and H2O2 levels were also higher in ventricular septal defect compared with controls, and NOx levels were lower in ventricular septal defect patients compared with tetralogy of Fallot and controls (p < 0.05).These data suggest that increased pulmonary blood flow from ventricular septal defect results in altered carnitine and mitochondrial homeostasis, decreased nitric oxide signaling, and increased reactive oxygen species production. These data are consistent with our animal data demonstrating that altered carnitine homeostasis results in mitochondrial dysfunction, increased reactive oxygen species production, and decreased bioavailable nitric oxide. Since disruption of carnitine metabolism may contribute to endothelial dysfunction, carnitine supplementation may attenuate endothelial dysfunction associated with increased pulmonary blood flow and warrants further investigation.

    View details for DOI 10.1097/PCC.0000000000001275

    View details for Web of Science ID 000412206900010

    View details for PubMedID 28723882

    View details for PubMedCentralID PMC5628126

  • Pushing the envelope: a treat and repair strategy for patients with advanced pulmonary hypertension associated with congenital heart disease PULMONARY CIRCULATION Kameny, R., Colglazier, E., Nawaytou, H., Moore, P., Reddy, V., Teitel, D., Fineman, J. R. 2017; 7 (3): 747-751

    Abstract

    Pulmonary arterial hypertension (PAH) is a frequent complication of congenital heart disease as a consequence of altered pulmonary hemodynamics with increased pulmonary blood flow and pressure. The development of pulmonary vascular disease (PVD) in this patient population is an important concern in determining operative strategy. Early, definitive surgical repair, when possible, is the best therapy to prevent and treat PVD. However, this is not possible in some patients because they either presented late, after the development of PVD, or they have complex lesions not amenable to one-step surgical correction, including patients with single ventricle physiology, who have a continuing risk of developing PVD. These patients represent an important, high-risk subgroup and many have been considered inoperable. We present a case series of two patients with complex congenital heart disease and advanced PVD who successfully underwent a treat and repair strategy with aggressive PAH therapies before surgical correction. Both patients had normalization of pulmonary vascular resistance prior to surgical correction. Caution is warranted in applying this strategy broadly and long-term follow-up for these patients is crucial. However, this treat and repair strategy may allow for favorable outcomes among some patients who previously had no therapeutic options.

    View details for DOI 10.1177/2045893217726086

    View details for Web of Science ID 000411119000024

    View details for PubMedID 28862067

    View details for PubMedCentralID PMC5841911

  • Pulmonary artery smooth muscle cell hyperproliferation and metabolic shift triggered by pulmonary overcirculation AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY Boehme, J., Sun, X., Tormos, K. V., Gong, W., Kellner, M., Datar, S. A., Kameny, R., Yuan, J., Raff, G. W., Fineman, J. R., Black, S. M., Maltepe, E. 2016; 311 (4): H944-H957

    Abstract

    Vascular cell hyperproliferation and metabolic reprogramming contribute to the pathophysiology of pulmonary arterial hypertension (PAH). An important cause of PAH in children with congenital heart disease (CHD) is increased pulmonary blood flow (PBF). To better characterize this disease course we studied early changes in pulmonary artery smooth muscle cell (PASMC) proliferation and metabolism using a unique ovine model of pulmonary overcirculation. Consistent with PAH in adults, PASMCs derived from 4-wk-old lambs exposed to increased PBF (shunt) exhibited increased rates of proliferation. While shunt PASMCs also exhibited significant decreases in mitochondrial oxygen consumption, membrane potential, and tricarboxylic acid (TCA) cycle function, suggesting a switch to Warburg metabolism as observed in advanced PAH in adults, they unexpectedly demonstrated decreased glycolytic lactate production, likely due to enhanced flux through the pentose phosphate pathway (PPP). This may be a response to the marked increase in NADPH oxidase (Nox) activity and decreased NADPH/NADP+ ratios observed in shunt PASMCs. Consistent with these findings, pharmacological inhibition of Nox activity preferentially slowed the growth of shunt PASMCs in vitro. Our results therefore indicate that PASMC hyperproliferation is observed early in the setting of pulmonary overcirculation and is accompanied by a unique metabolic profile that is independent of HIF-1α, PDHK1, or increased glycolytic flux. Our results also suggest that Nox inhibition may help prevent pulmonary overcirculation-induced PAH in children born with CHD.

    View details for DOI 10.1152/ajpheart.00040.2016

    View details for Web of Science ID 000390116100008

    View details for PubMedID 27591215

    View details for PubMedCentralID PMC5114466

  • Disrupted NOS signaling in lymphatic endothelial cells exposed to chronically increased pulmonary lymph flow AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY Datar, S. A., Gong, W., He, Y., Johengen, M., Kameny, R. J., Raff, G. W., Maltepe, E., Oishi, P. E., Fineman, J. R. 2016; 311 (1): H137-H145

    Abstract

    Associated abnormalities of the lymphatic circulation are well described in congenital heart disease. However, their mechanisms remain poorly elucidated. Using a clinically relevant ovine model of a congenital cardiac defect with chronically increased pulmonary blood flow (shunt), we previously demonstrated that exposure to chronically elevated pulmonary lymph flow is associated with: 1) decreased bioavailable nitric oxide (NO) in pulmonary lymph; and 2) attenuated endothelium-dependent relaxation of thoracic duct rings, suggesting disrupted lymphatic endothelial NO signaling in shunt lambs. To further elucidate the mechanisms responsible for this altered NO signaling, primary lymphatic endothelial cells (LECs) were isolated from the efferent lymphatic of the caudal mediastinal node in 4-wk-old control and shunt lambs. We found that shunt LECs (n = 3) had decreased bioavailable NO and decreased endothelial nitric oxide synthase (eNOS) mRNA and protein expression compared with control LECs (n = 3). eNOS activity was also low in shunt LECs, but, interestingly, inducible nitric oxide synthase (iNOS) expression and activity were increased in shunt LECs, as were total cellular nitration, including eNOS-specific nitration, and accumulation of reactive oxygen species (ROS). Pharmacological inhibition of iNOS reduced ROS in shunt LECs to levels measured in control LECs. These data support the conclusion that NOS signaling is disrupted in the lymphatic endothelium of lambs exposed to chronically increased pulmonary blood and lymph flow and may contribute to decreased pulmonary lymphatic bioavailable NO.

    View details for DOI 10.1152/ajpheart.00649.2015

    View details for Web of Science ID 000384969700014

    View details for PubMedID 27199125

    View details for PubMedCentralID PMC4967199

  • Right ventricular nitric oxide signaling in an ovine model of congenital heart disease: a preserved fetal phenotype AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY Kameny, R., He, Y., Morris, C., Sun, C., Johengen, M., Gong, W., Raff, G. W., Datar, S. A., Oishi, P. E., Fineman, J. R. 2015; 309 (1): H157-H165

    Abstract

    We recently reported superior right ventricle (RV) performance in response to acute afterload challenge in lambs with a model of congenital heart disease with chronic left-to-right cardiac shunts. Compared with control animals, shunt lambs demonstrated increased contractility because of an enhanced Anrep effect (the slow increase in contractility following myocyte stretch). This advantageous physiological response may reflect preservation of a fetal phenotype, since the RV of shunt lambs remains exposed to increased pressure postnatally. Nitric oxide (NO) production by NO synthase (NOS) is activated by myocyte stretch and is a necessary intermediary of the Anrep response. The purpose of this study was to test the hypothesis that NO signaling is increased in the RV of fetal lambs compared with controls and shunt lambs have persistence of this fetal pattern. An 8-mm graft was placed between the pulmonary artery and aorta in fetal lambs (shunt). NOS isoform expression, activity, and association with activating cofactors were determined in fetal tissue obtained during late-gestation and in 4-wk-old juvenile shunt and control lambs. We demonstrated increased RNA and protein expression of NOS isoforms and increased total NOS activity in the RV of both shunt and fetal lambs compared with control. We also found increased NOS activation and association with cofactors in shunt and fetal RV compared with control. These data demonstrate preserved fetal NOS phenotype and NO signaling in shunt RV, which may partially explain the mechanism underlying the adaptive response to increased afterload seen in the RV of shunt lambs.

    View details for DOI 10.1152/ajpheart.00103.2015

    View details for Web of Science ID 000357502700015

    View details for PubMedID 25934095

    View details for PubMedCentralID PMC4491525